AbbVie (ABBV) Enterprise Value (2012 - 2026)
AbbVie (ABBV) posted quarterly Enterprise Value of -$9.3 billion for Q1 2026, down 82.06% YoY from -$52.1 billion in Q1 2025, and down 79.23% sequentially from -$5.2 billion in Q4 2025.
AbbVie (ABBV) Enterprise Value (2012 - 2026) Analysis & Trends
AbbVie has disclosed Enterprise Value across 15 years of filings, most recently posting -$9.3 billion for Q1 2026.
- In Q1 2026, Enterprise Value fell 82.06% year-over-year to -$9.3 billion; the TTM figure through Mar 2026 stood at -$9.3 billion (down 82.06% YoY), while the FY2025 annual figure was -$5.2 billion, up 5.46% from the prior year.
- Enterprise Value slipped to -$9.3 billion in Q1 2026, from -$5.2 billion in the prior quarter.
- Over the last five years, Enterprise Value for ABBV reached as high as -$5.1 billion in Q1 2025 and fell as low as -$18.0 billion in Q1 2024.
- The 5-year median for Enterprise Value is -$8.7 billion (2023), against an average of -$9.2 billion.
- Annual changes were most pronounced in 2024 — Enterprise Value sank 169.37% — and 2025, when it surged 71.52%.
- A 5-year view of Enterprise Value shows it stood at -$9.2 billion in 2022, then sank by 38.96% to -$12.8 billion in 2023, then jumped by 56.84% to -$5.5 billion in 2024, then advanced by 5.46% to -$5.2 billion in 2025, then sank by 79.23% to -$9.3 billion in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$9.3 billion, -$5.2 billion, and -$5.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -22.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -9.35 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -7.89 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 315.00 Mn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | -4.28 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9.35 Bn |
| Dec 31, 2025 | -5.22 Bn |
| Sep 30, 2025 | -5.63 Bn |
| Jun 30, 2025 | -6.42 Bn |
| Mar 31, 2025 | -5.13 Bn |
| Dec 31, 2024 | -5.52 Bn |
| Sep 30, 2024 | -7.25 Bn |
| Jun 30, 2024 | -13.11 Bn |
| Mar 31, 2024 | -18.03 Bn |
| Dec 31, 2023 | -12.78 Bn |
| Sep 30, 2023 | -13.26 Bn |
| Jun 30, 2023 | -8.73 Bn |
| Mar 31, 2023 | -6.69 Bn |
| Dec 31, 2022 | -9.20 Bn |
| Sep 30, 2022 | -11.85 Bn |
| Jun 30, 2022 | -9.93 Bn |
| Mar 31, 2022 | -7.54 Bn |
| Dec 31, 2021 | -9.80 Bn |
| Sep 30, 2021 | -12.22 Bn |
| Jun 30, 2021 | -8.58 Bn |